Catalyst
Slingshot members are tracking this event:
Mylan (MYL) Senate Hearing Regarding Pricing of EpiPen on November 30th
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MYL |
|
|
||||
Additional Information
- The Senate Judiciary Committee has postponed its hearing on EpiPen pricing as it "considers other avenues to ensure government and company witnesses participate."
- The hearing was scheduled for November 30 but Mylan, representatives of the Justice Department and the Centers for Medicare & Medicaid Services (CMS) stated that they would not be able to attend due to "pending matters and investigations."
- At issue is whether Mylan underpaid government healthcare plans by classifying EpiPen as generic in the Medicaid Drug Rebate Program.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 01, 2016
Occurred Source:
http://www.forbes.com/sites/arleneweintraub/2016/12/01/mylan-ceo-bresch-admits-full-responsibility-for-epipen-price-hikes/
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Senate, Epipen, Pricing
